# Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection

> **NCT01872936** · PHASE2 · UNKNOWN · sponsor: **Santaris Pharma A/S** · enrollment: 20 (estimated)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Miravirsen
- **DRUG:** Telaprevir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01872936
- **Lead sponsor:** Santaris Pharma A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-06
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2014-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01872936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01872936, "Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01872936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*